Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma
December 09, 2024 19:30 ET
|
Ichnos Glenmark Innovation
IGI Presents 1st Clinical Data from Ph 1 Study of Trispecific Antibody, ISB 2001, Showing High ORR & Favorable Safety Profile in Heavily Treated RRMM Pts.
Ichnos Glenmark Innovation (IGI) présente les données cliniques initiales issues de l’étude de phase 1 portant sur l’anticorps trispécifique TREAT™, ISB 2001, démontrant un taux de réponse globale (TRG) élevé avec des réponses durables et un profil d’innocuité favorable chez des patients atteints d’un myélome multiple lourdement prétraités
December 09, 2024 19:30 ET
|
Ichnos Glenmark Innovation
Aucune toxicité limitant la dose n’a été observée avec des doses sous-cutanées hebdomadaires jusqu’à 1,2 mg/kg, et principalement, un léger syndrome de relargage des cytokines a été observé. Aucun cas...
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
December 09, 2024 19:30 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Carbon Dioxide Market is Slated to Develop at a Modest 5.1% CAGR through 2031 | SkyQuest Technology
December 09, 2024 19:30 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the carbon dioxide market size will attain a value of USD 15.93 billion by 2031, with a CAGR of 5.1% over the forecast period...
Sirios Resources Announces Closing of a Second Tranche of $849,000 of its Flow-Through Private Placement
December 09, 2024 19:25 ET
|
Sirios Resources Inc.
Clôture d'un financement privé accréditif de 849 000$ par Sirios
Sirios closes of a Flow-Through Share private financing of 849,000$
ThreeD Capital Inc. Announces Unaudited November 30, 2024 Net Asset Value Per Share – $0.77
December 09, 2024 19:20 ET
|
ThreeD Capital Inc
TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in...
Coffee With Q Podcast News Reporter Rene Perras Explores Medical Errors and Misdiagnosis with Renowned Lawyer Joe Osborne
December 09, 2024 19:00 ET
|
Coffee With Q Podcast Show
George Town, Grand Cayman , Dec. 09, 2024 (GLOBE NEWSWIRE) -- The Coffee With Q podcast, hosted by Rene Perras, has released another insightful episode featuring Joe Osborne, a leading civil...
Cassius Ventures Ltd. Announces Arrangements to Address Mailing Delays as a Result of The Canada Post Strike
December 09, 2024 19:00 ET
|
Cassius Ventures Ltd.
VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cassius Ventures Ltd. (the “Company”) reports that, due to the ongoing Canada Post postal strike, delivery of the notice of meeting,...
Five9, Inc. Shareholder Notice: Robbins LLP Reminds Investors of the FIVN Class Action
December 09, 2024 18:50 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Five9, Inc. (FIVN) Misled Investors Regarding its Sales Execution and Efficiency Issues
Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit
December 09, 2024 18:38 ET
|
Block & Leviton LLP
Block & Leviton announces that a securities fraud lawsuit has been filed against Kyverna Therapeutics (Nasdaq: KYTX). Investors should contact the firm.
- December 20, 2024 19:06 ET Darrell Kelley Releases Fascinating New Single “Drones”
- December 20, 2024 18:41 ET Mustang Energy Continues to Build Land Portfolio with Acquisition of 17,929 Hectares South of the Athabasca Basin, Saskatchewan